Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Digital technology now offers unprecedented opportunity for patients to be actively involved in monitoring and managing their chronic cardiovascular conditions. Patients have access to low-cost devices that can monitor heart rate continuously, record an electrocardiogram, quantitate daily physical activity and measure blood oxygen saturation as well as body weight and home blood pressure measurements. However, we need to ensure that patient self-monitoring is implemented in ways that improve quality of life and clinical outcomes.
In this issue of Heart, Rahimi and colleagues1 report a clinical trial of 202 high-risk patients with heart failure (HF) randomised to home self-monitoring of weight and blood pressure versus additional centralised specialist feedback to the patient about self-management and to the patient’s primary provider about recommended blood tests and medical therapy. Interestingly, there was no difference between groups in use of guideline-recommended medical therapy or in patient’s physical well-being. In addition, there were no significant differences in cardiovascular events, hospital admissions or mortality (table 1).
These disappointing results lead us to ask, as queried in an editorial by Dardas and Dorsch,2 ‘What factors led to this negative finding and to the increasingly large body of work demonstrating little effect of mobile health (mHealth) technologies on patient outcomes?’ Some issues they discuss include the challenges using a central clinical management team acting asynchronously outside the patient’s normal care team; the inclusion of both patients with HF with preserved ejection fraction and HF with reduced ejection fraction (HFrEF) which might dilute any benefit in those with HFrEF; and the infrequent change in medications in the HFrEF patients. They note that ‘The path between data acquisition and outcome reduction is elusive and must ultimately converge on timely delivery of treatment that affects health and well-being.’ In my view, we also need to involve patients more actively in the design, implementation and presentation of studies using home-based digital monitoring of chronic cardiovascular disease. Obviously, patient-centred care requires a central role for patients in research and implementation of new strategies to improve health.
The optimal approach to ‘ruling out’ an acute coronary syndrome (ACS) in the emergency department remains controversial. In a randomised controlled trial of 632 patients (mean age 54 years, 41% female) from eight hospitals in the UK, Carlton and colleagues3 found that with a strategy based on an undetectable high-sensitivity cardiac troponin (hs-cTn) and non-ischaemic ECG (limit of detection and ECG discharge (LoDED)), 46% were discharged within 4 hours, compared with 37% in the usual care group (figure 1). There was no difference in major adverse cardiac events at 30 days comparing the LoDED strategy to usual care (OR 1.50, 95% CI 0.76 to 3.02).
In an editorial, Lee and Mills4 point out that there have been few randomised controlled clinical trials evaluating the safety and efficacy of rule-out pathways based on a very low hs-cTn, even though this approach is widely used and is recommended in clinical guidelines. However, ‘the LoDED trial did not demonstrate that using a high-sensitivity cardiac troponin concentration below the limit of detection at presentation was more effective than usual care to rule-out myocardial infarction in the emergency department.’ Potential reasons why this trial did not demonstrate a meaningful difference in efficacy between usual care and the LoDED strategy include: (1) many of the participating hospitals were already using a limit of detection threshold for hs-cTn, (2) the study may be underpowered to detect a significant difference between strategies, (3) the trial population was relatively young and low-risk compared with unselected patients with suspected ACS and (4) a higher hs-cTn threshold may have greater efficacy with similar safety. ‘Nevertheless, there were a number of encouraging insights which require further investigation. The LoDED trial and other randomised controlled trials addressing this topic are much needed to raise the quality of evidence used to inform national and international clinical practice guidelines.’
Although infrequently seen by most cardiologists, a particularly vexing clinical problem is incessant or recurrent pericarditis (RP) which can lead to constrictive pericarditis (CP). Andreis and colleagues5 hypothesised that treatment with anakinra, an interleukin-1 inhibitor, could treat CP due to incessant or RP and reduce the need for surgical pericardiectomy, which is associated with a high operative mortality and morbidity. In a study of 39 patients with recurrent or incessant pericarditis dependent on chronic glucocorticoids (GCs) and resistant to colchicine therapy, CP developed in 20% of patients, most often those with incessant pericarditis, and reversed with use of anakinra in 5 of these 8 patients (63%).
This data is put into context by Lazaros and Tousoulis6 who remind us that although pericarditis accounts for up to about 50% of CP cases, other causes include post-cardiac surgery (11%–37%), irradiation therapy (9%–31%), connective tissue disorders (3% to 7%), tuberculosis or bacterial pericarditis (3%–6%) and less common causes (<10%) such as malignancy, trauma and uraemia. They point out that ‘the study of Andreis et al 5 is the first one that has systematically assessed the impact of anakinra administration in patients with GC-dependent colchicine-resistant RP and clinical features of CP.’ Additional remarkable findings are the unexpectedly high rate (20%) of CP observed in patients with GC-dependent colchicine-resistant pericarditis and the extremely rapid progression of GC-dependent colchicine-resistant pericarditis. ‘Taking into account the most recent ESC guidelines on pericardial syndromes, the updated experience on anakinra administration in pericardial diseases and the aforementioned paper results, we propose the algorithm depicted in figure 2 as a practical guide for the management of CP.’
As we continue to balance the care of our patients with cardiovascular disease against the sometimes-limited healthcare resources due to the COVID-19 pandemic, useful guidance is provided in a review article on management of patients with heart valve disease, particularly aortic stenosis (figure 3), following the pandemic7 and an Education in Heart article on management of patients with ACSs.8
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.